Yorulmaz Enis Mert, Donmez Kursad, Ozcan Serkan, Kose Osman, Gorgel Sacit Nuri, Candemir Enes, Akin Yigit
Department of Urology, Izmir Katip Celebi University, Izmir 35620, Turkey.
Department of Urology, Ataturk Research and Training Hospital, Izmir 35360, Turkey.
Diagnostics (Basel). 2025 Jul 22;15(15):1840. doi: 10.3390/diagnostics15151840.
: Upper tract urothelial carcinoma (UTUC) is often complicated by intravesical recurrence and cancer progression following radical nephroureterectomy (RNU). Identifying reliable prognostic biomarkers remains crucial for optimizing postoperative surveillance. The goal of this study was to assess the prognostic value of the De Ritis ratio (AST/ALT) in predicting bladder recurrence and oncologic outcomes in patients with clinically localized UTUC undergoing RNU. : This retrospective study analyzed 87 patients treated with RNU between 2018 and 2025. Preoperative De Ritis ratios were calculated, and an optimal cut-off value of 1.682 was determined using ROC analysis. Recurrence-free survival (RFS), cancer-specific survival (CSS), and overall survival (OS) were analyzed using the Kaplan-Meier and Cox regression methods. Logistic regression was used to identify independent predictors of bladder recurrence. : A high De Ritis ratio was significantly associated with increased bladder recurrence and worse RFS and CSS, but not OS. Multivariate analysis confirmed that an elevated De Ritis ratio, current smoking, positive surgical margins, and synchronous bladder cancer were the independent predictors of bladder recurrence. The De Ritis ratio demonstrated strong discriminatory performance (AUC: 0.807), with good sensitivity and specificity for predicting recurrence. : The De Ritis ratio is a simple, cost-effective preoperative biomarker that may aid in identifying UTUC patients at higher risk for intravesical recurrence and cancer-specific mortality. Incorporating this ratio into clinical decision-making could enhance risk stratification and guide tailored follow-up strategies.
上尿路尿路上皮癌(UTUC)在根治性肾输尿管切除术(RNU)后常并发膀胱内复发和癌症进展。识别可靠的预后生物标志物对于优化术后监测仍然至关重要。本研究的目的是评估德瑞蒂斯比值(AST/ALT)在预测接受RNU的临床局限性UTUC患者膀胱复发和肿瘤学结局方面的预后价值。
这项回顾性研究分析了2018年至2025年间接受RNU治疗的87例患者。计算术前德瑞蒂斯比值,并使用ROC分析确定最佳临界值为1.682。采用Kaplan-Meier法和Cox回归法分析无复发生存期(RFS)、癌症特异性生存期(CSS)和总生存期(OS)。采用逻辑回归确定膀胱复发的独立预测因素。
高德瑞蒂斯比值与膀胱复发增加、RFS和CSS较差显著相关,但与OS无关。多因素分析证实,德瑞蒂斯比值升高、当前吸烟、手术切缘阳性和同步性膀胱癌是膀胱复发的独立预测因素。德瑞蒂斯比值表现出较强的鉴别性能(AUC:0.807),对预测复发具有良好的敏感性和特异性。
德瑞蒂斯比值是一种简单、经济有效的术前生物标志物,可能有助于识别膀胱内复发和癌症特异性死亡风险较高的UTUC患者。将该比值纳入临床决策可以加强风险分层并指导个性化的随访策略。